Amber Specialty Pharmacy Begins Administering Bamlanivimab in Long-Term Care Facilities in Five Cities Across the U.S.

Business Wire

Published

OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy – a subsidiary of Hy-Vee, Inc. – announces today that it has begun administering the FDA-approved infusion treatment bamlanivimab (BAM) to long-term care facility residents and staff in several cities across the United States. Amber is one of a few select home-infusion providers authorized to administer this new antibody treatment to combat COVID-19. Beginning this week, Amber and Hy-Vee will receive doses to administer at long-term care fa

Full Article